×

img Accessibility Controls

Technologies Banner

All Technologies

Repurposing of Umifenovir against COVID-19

Project Overview

An economical process technology has been developed using indigenously available key starting materials. CSIR-CDRI has received the permission from Central Drugs Standard Control Organization for conducting the Phase III clinical trial with Umifenovir entitled "Randomised, double blind, placebo controlled trial of efficacy, safety and tolerability of Antiviral drug Umifenovir vs standard care of therapy in non-severe COVID-19 patients.”

Source

Quick Information
Thrust Areas
COVID-19 Research
Focus Area
Development of Repurposed Drugs for COVID-19
Output
TRL: Technology Readiness Level
Technology development
Company Transferred To
Medizest Pharmaceuticals Pvt. Ltd., Goa
arrowtop
Latest Updates
Loading…